Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation

BACKGROUND: To date, there is no information on the safety and efficacy of the novel anti-sarbecoviruses monoclonal antibody sotrovimab administered, as a post-exposure prophylactic measure, during the aplastic phase of autologous stem cell transplantation (ASCT). METHODS: We describe the outcomes o...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcacci, Gianpaolo, Coppola, Nicola, Madonna, Emanuela, Becchimanzi, Cristina, De Pascalis, Stefania, D’Ovidio, Silvia, Crisci, Stefania, Maiolino, Piera, De Filippi, Rosaria, Pinto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351203/
https://www.ncbi.nlm.nih.gov/pubmed/35922822
http://dx.doi.org/10.1186/s13027-022-00454-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351203/
https://www.ncbi.nlm.nih.gov/pubmed/35922822
http://dx.doi.org/10.1186/s13027-022-00454-y

Ejemplares similares